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Abstract 
Introduction:  Inappropriate use of medicines remains a problem, with consequences including 
increasing adverse drug reactions (ADRs) and prolonged hospitalizations. The Essential Medicines 
List and Drug and Therapeutics Committees (DTCs) are accepted initiatives to promote the rational 
use of medicines. However, little is known about DTC activities in Nigeria, the most populous African 
country. Areas covered: A cross-sectional questionnaire-based study was conducted among senior 
pharmacists, consultant physicians and clinical pharmacologists in 12 leading tertiary healthcare 
facilities across Nigeria. Expert commentary:  Six (50%, 6/12) healthcare facilities had existing DTCs 
with three (50%) having a sub-committee on antimicrobials. 75% had infection control committees, 
with presence even in centres without DTCs. Chairpersons and secretaries of the DTCs were 
predominantly physicians (83.3%) and pharmacists (100%) respectively. Hospital formularies were 
available in five facilities with DTCs, while one facility without a DTC had an Essential Medicines 
Committee responsible for developing and updating the hospital formulary. The evaluation of ADRs 
was undertaken by pharmacovigilance units in nine facilities. Overall, DTCs were present in only half 
of the surveyed facilities and most were performing their statutory functions sub-optimally. The 
functioning of DTCs can be improved through government directives and mechanisms for continuous 
evaluation of activities.  
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1. Introduction  
Inappropriate use of medicines is a global problem with wide consequences including adverse drug 
reactions (ADRs), therapeutic failure, prolonged hospitalization, development of drug resistance, 
inefficiencies in the procurement of medicines and increased healthcare costs (1, 2). Development of 
drug resistance, especially antimicrobial resistance (AMR), is a growing public health problem 
worldwide (3-6). 
 
The World Health Organization (WHO), with the Essential Medicines List (EML) and Drug and 
Therapeutics Committees (DTCs) concepts, initiated efforts to address the irrational use of medicines 
in the 1970s (7-10). A DTC is defined as a professional body that evaluates the clinical use of 
medicines, manages and supports evidence-based use of medicines through a formulary system and 
deals with policy issues of medicine use. The principal functions of DTCs include the evaluation and 
selection of drugs for the formulary, supporting the Rational Use of Medicines (RUM) in the hospital, 
as well as continuous medical education initiatives to improve the use and dispensing of medicines 
(11).  
 
Studies in high income countries have highlighted the importance of DTCs in the promotion of RUM, 
and the cost-effective use of medicines, through learning with adherence to recommendations 
regarding prescribing enhanced through trust in those compiling the formulary (12-15). A few studies 
have described DTCs among lower and middle income countries (LMICs), but their functionality and 
mode of operation are poorly reported (16-18).   
 
In Nigeria, there is considerable evidence regarding the inappropriate use of medicines. This is a 
concern since out of pocket payments (OOP) currently constitutes the major component of healthcare 
expenditure, negatively impacting on available choices of medicines to effectively treat both infectious 
and non-communicable diseases (19, 20). Consequently, any initiative that would positively impact on 
RUM in Nigeria should be a priority for the country. In this regard, the role of functional DTCs cannot 
be overemphasized. The National Drug Policy of Nigeria recognizes DTCs as a vital component with 
initial targets of institutionalizing the committees in secondary and tertiary healthcare facilities (21). 
However, presently there is little information regarding the presence and functionality of DTCs in 
hospitals or other health care facilities in Nigeria. This lack of information was the basis for this study.  
 
The main objective of this study was to determine the availability and functionality of DTCs among 
tertiary healthcare facilities across Nigeria. The findings can be used to guide future activities in 
Nigeria to enhance the appropriate use of medicines as well as other African countries in similar 
circumstances. 
 
2. Methods 
2.1 Study setting 
This study was undertaken among public sector tertiary healthcare facilities located across Nigeria, a 
country with an estimated population of over 187 million (22). Nigeria is divided into six geo-political 
zones and has 36 federal States and one Federal Capital Territory. Healthcare services are provided 
by both private and public healthcare facilities. The public healthcare system is stratified into three 
levels: primary, secondary and tertiary care. The primary level comprises health centres, while the 
secondary level comprises general hospitals. The tertiary healthcare level comprises Federal Medical 
Centres, University Teaching Hospitals, as well as specialized hospitals including orthopaedic and 
neuro-psychiatric hospitals. Presently, there are 50 university teaching hospitals owned by the federal 
or state governments (23). The tertiary level hospitals are the best-equipped facilities in terms of 
personnel and many have postgraduate training programmes for medical doctors, pharmacists, 
nurses and other healthcare staff. Consequently, if there are problems with fully functioning DTCs in 
tertiary hospitals, these are likely to be exacerbated in secondary care hospitals with less qualified 
personnel including typically a lack of clinical pharmacologists, pharmacists, and others well versed 
specialists in RUM. 
 
2.2 Study design 
A descriptive cross-sectional survey conducted between 1st and 30th April, 2016, using a self-
administered questionnaire was undertaken. 
 
2.3 Sample 
Purposive convenience sampling was undertaken, using hospitals with reliable personal contacts. 
Three tertiary healthcare facilities in each of the five geo-political regions (24) (Figures 1) of the 
country were selected for the study though questionnaires were sent to four in each zone to cater for 
non-responders. Tertiary healthcare facilities were selected as they have the most qualified cadre of 
personnel. The North-eastern zone of the country was excluded because of ongoing militant 
insurgency during the study period.  
 
 
2.4 Data collection instrument 
A DTC Questionnaire (Annex 1), which is a standard instrument developed by the World Health 
Organization (WHO) and Management Sciences for Health (MSH), was used for this study (25, 26).  
 
2.5 Data collection process 
The questionnaires were sent by email to the focal persons of the selected institutions after initial 
contact by telephone. The focal person for each selected tertiary hospital was a senior pharmacist, a 
clinical pharmacologist or a consultant physician. A time frame of one month was allowed for the 
return of the completed questionnaires. 
 
2.6 Data analysis 
Data from the questionnaires were coded and entered into an MS Excel spreadsheet, cleaned, and 
imported into SPSS version 19 (IBM Corporation, Armonk, NY, USA) for analysis. Results were 
expressed as means, frequencies and percentages. For the non-quantitative data, content analysis 
using themes was used. 
 
2.7 Ethical considerations 
The study was exempted from ethical approval according to the National Code of Health Research 
Ethics of Nigeria because it dealt with information of existing programme or services with the primary 
aim of improvement in the outcomes (27).  
 
3. Results 
Responses were received from 12 (60%) out of 20 tertiary healthcare facilities approached. These 
covered all the geopolitical zones apart from the North-eastern region (Figure 1). Six (50%) of the 12 
tertiary healthcare facilities had existing DTCs with various durations of operation (Range: 1-16 
years). Four (66.7%) of the DTCs in the six facilities with DTCs held meetings at variable intervals 
(monthly to 6-monthly), with minutes of the meetings being kept by all DTCs . 
 
Figure 1 – Geopolitical Zones of Nigeria and Hospitals Taking Part (adapted from (24)) 
 
 
 
Hospitals taking part: South-West -4; South-East- 1; South-South- 1; North-Central- 4; North-West- 2 
 
The chair and secretary of the DTCs were predominantly physicians (83.3%) and pharmacists (100%) 
respectively. Membership of the operational DTCs included physicians, pharmacists, nurses, 
laboratory technologists and administrative staff. Table 1 gives information about availability of DTCs 
and its’ core functions in the surveyed healthcare facilities. Information about existence or otherwise 
of the core components of DTCs within each of the 12 participating hospitals including antimicrobial 
sub-committees, infection control sub-committees, operational guidelines and quality assurance of 
medicines are shown in Figure 2.  
 
Table 1: Information about availability of core components and functions of DTCs in Nigeria 
 
Questions/Statements Response (Yes) Response(No)  
Does your hospital have a DTC 6 6  
Does your DTC have a Sub-committee on Antimicrobials? 3 9  
Does your hospital have an Infection Control Committee? 9 3  
Does your DTC have guidelines and procedures that 
regulate the functions of DTC 
5 7  
Does your hospital have a medicine formulary?  6 6  
Is there a medicine information centre in your hospital? 9 3  
Does your DTC have a policy for evaluating adverse drug 
reactions? 
9 3  
Does your DTC have established policies to assure 
product quality 
5 7  
Does your DTC participate in preparing technical 
specifications for procurement of Medicines? 
3 9  
Does your DTC participate in evaluating pharmaceutical 
costs and providing information back to the physician 
3 9  
Does your DTC have established methods for periodically 
evaluating the use of medicines in the hospital and 
providing feedback to the physicians? 
2 10  
 
 
Figure 2 – DTC activities within each of the 12 participating Tertiary Hospitals 
 
 
The reported functions of these DTCs included development and periodic review of hospital drug 
formularies, surveillance of antimicrobial use, pharmacovigilance activities and monitoring the use of 
narcotics . Other identified functions included the development of standard treatment guidelines 
(STGs) and infection control guidelines. Hospital formularies were available in five (83.3%) healthcare 
facilities with DTCs, while one facility without a DTC had an Essential Medicines Committee, which 
was responsible for developing and updating the hospital formulary.  
 
Medicines were listed in hospital formularies by generic name or International Non-proprietary Name 
(INN) in five (83.3%) healthcare facilities, while brand (originator) names were included in one 
(16.7%) facility. The hospital formularies, where they did exist, were modelled on the WHO Essential 
Medicines List (EML) concept. The number of chemical entities included in the hospital formularies, 
as specified by their INN, varied between 210 and 720. The hospital formularies were usually 
available in hard copy and distributed to the hospital’s clinics, wards and pharmacies. An electronic 
version of the formulary was not available in any of the healthcare facilities.  
  
The time frame of updating the formulary varied from twice yearly to once every three years. Only two 
centres with DTCs had a revision every two years or less. The procedures for updating the formulary 
varied between the centres and included submission of requests by clinicians to the DTC. 
Pharmaceutical sales representatives also appeared to play a significant role in the process of 
updating the formulary through making presentations at various clinical departments and providing 
product information for evaluation by the DTC.  
 
4. Discussion 
 
The results from this survey showed that DTCs had not been instigated in half of the surveyed tertiary 
healthcare facilities, and were functioning sub-optimally where present. These findings are similar to 
results from a Brazilian study where only 29 out of 250 hospitals had DTCs (28). This is in contrast 
though to findings from studies carried out in Europe and Australia where DTCs were present in more 
than 90% of hospitals surveyed in both continents (29, 30), have to be present by law in Sweden (31), 
and are now required in all public sector hospitals in South Africa (18).  
 
DTCs, especially its sub-committee on antimicrobials, are one of the main strategies for improving 
antimicrobial use and combating AMR in hospitals especially in low and middle income countries 
(18,32). A major concern in Nigeria is that among tertiary facilities, only three hospitals had such a 
committee. However, we cannot say this with certainty until we evaluate the situation in these 
hospitals. This finding may though be due to possible overlap of the functions of the sub-committees 
and one dealing specifically with infection control, which was available in 75% of the surveyed 
healthcare facilities. These findings are similar to a Canadian study as well as a South African study, 
which revealed just about one third of DTCs have a sub-committee on antimicrobials (18, 33). 
 
Members of DTCs in this study included physicians, pharmacists, nurses and laboratory scientists, 
which is similar to other countries (33, 34). While membership from all areas of medicine is important, 
trust and a transparent means of deliberation and decision making have been found to be core 
ingredients of successful DTC operations (12, 14). Most of the functions of DTCs reported in this 
study centered on drug formulary development and review, monitoring of ADRs and antimicrobial use, 
similar to studies conducted in Australia and Canada (30, 33). However, this is different from South 
Africa where the majority of activities centered on formulation and policies surrounding medicine use, 
development of formularies and monitoring medicines’ expenditure (18).  
 
One of the major functions of the DTCs is to assist with selecting cost-effective medicines, especially 
with the rising costs of new medicines, including those for cancer and orphan diseases (13, 28, 31, 
35-37). However, this was not the case in our study, with only three out of 12 healthcare facilities 
currently performing any form of economic evaluation of proposed medicines, and this activity was not 
listed among the main functions of the DTCs. Similarly, a lack of expertise in pharmacoeconomics 
and evidence-based decision-making was identified as a challenge amongst hospital DTCs in a South 
African province (18). This omission is a potential concern in Nigeria as cost savings should be the 
priority of many developing countries where health insurance is not universal and a large percentage 
of healthcare spending is usually “out of pocket”. This will be followed up in future research. 
 
The overall lack of hospital formularies in many of the surveyed tertiary healthcare facilities is also a 
major concern. The lack of formularies suggests that there is no control in the number and scope of 
medicines that may be prescribed by physicians even in these tertiary healthcare facilities. In this 
situation, it becomes extremely challenging to monitor medicine prescribing in practice leading to 
potentially a lack of adherence to agreed treatment guidelines. The non-availability of electronic 
versions of hospital formularies is also an issue that needs urgent attention. With broadened access 
to the internet and smartphones in many LMICs, electronic version of formularies would likely 
increase access to them as well as promote their use among healthcare professionals. The positive 
aspect of using electronic versions of guidelines has been demonstrated in the Netherlands with their 
national antibiotic policy (38). There is also good adherence to prescribing guidelines in Sweden with 
suggested medicines listed in electronic formularies and monitored (12, 13). Amongst LMICs, clinical 
guidelines have been available in electronic format as a mobile application in South Africa since the 
end of 2015. These are now being updated continuously as changes are made to the EMLs and 
STGs (39) to help enhance appropriate medicine use. This is a consideration for all hospitals in 
Nigeria in the future with the extensive availability of mobile technology.  
 
The number of medicines listed in hospital formularies in our study ranged from 210 to 720. However, 
formularies at the higher end of the range may be counter-productive as the major objective of an 
EML or hospital formulary is to limit the number of medicines to the barest manageable minimum.  
This is exemplified by the latest versions of the Stockholm ”Wise List” (excluding medicines for 
specialist conditions) and the Nigerian EML which contain 212 and 350 entities, respectively (13, 14, 
40). Observations of 13 DTC meetings in a South African province also revealed that all DTCs had an 
active formulary committee, working towards alignment with the national EML (18). This serves as an 
exemplar to Nigeria.   
 
Encouragingly, almost all healthcare facilities with DTCs had medicines listed in the hospital formulary 
by generic name. Studies have shown that prescribing by generic name (INN) reduces healthcare 
costs significantly (41, 42), which is beneficial in LMICs where universal health care is very variable. 
However, the quality of generics has to be assured, similar to regulations in Europe and the US, for 
physicians to be comfortable to prescribe using the INN, as seen for instance in the UK with very high 
voluntary INN prescribing apart from a limited number of medicines (43). There have been concerns 
with the quality of generics in some LMICs, including Nigeria, impacting on their prescribing (20, 44). 
This needs to be urgently addressed in Nigeria for all key stakeholder groups to benefit from the 
increasing availability of standard medicines as low-cost generics. 
 
The hospital formulary was updated infrequently as only two DTCs had revisions every two years or 
less. This is not surprising as the update of the fourth to fifth edition of the Nigerian National Essential 
Medicines List took over 7 years to complete (40). In addition, there seems to be no form of regulatory 
oversight regarding adherence to the National Essential Medicines List by healthcare facilities, with 
adherence to nationally agreed guidelines seen as an important marker of the quality of prescribing 
(12-14, 45,46). Pharmaceutical companies also play a significant role in the introduction of new 
medicines through presentations to clinical departments. The interactions between pharmaceutical 
sales representatives and physicians, and its implications regarding prescribing practices of 
physicians, have been widely reported in studies from developed countries and LMICs (47, 48). The 
quality of information provided by pharmaceutical sales representatives and their activities though 
remains a core issue alongside their influence (49, 50). This is also seen in Nigeria causing concern 
(51). These concerns have resulted in some hospitals banning promotional activities to improve future 
care (52). If this is not possible, the development and enforcement of guidelines for pharmaceutical 
sales representatives is an important DTC activity. However, this is not optimal across countries 
including South Africa, where only 11 of 19 hospital DTCs in one Province indicated this as a DTC 
activity (18). Having said this at national level in South Africa, dossiers from pharmaceutical 
companies are not considered in the selection of medicines and are regarded as having bias (53).  
 
Overall, the safety profile, cost-effectiveness and efficacy of medicines are seen as very important 
considerations when introducing new medicines into the hospital formulary (12, 54-57). To do this 
effectively, members of DTCs must have access to, and be able to interpret clinical trials data, while 
some understanding of pharmacoeconomic analyses is also increasingly essential (18, 58). This 
again was not the case among most of the surveyed tertiary healthcare facilities in Nigeria. The 
periodic assessment of adherence to hospital drug formularies, using physicians’ prescriptions, is also 
essential to promote RUM; however, only two healthcare facilities surveyed currently perform some 
form of periodic assessment. The usefulness of this approach is shown in Sweden with reports of high 
adherence levels (over 90%) by physicians to the “Wise List” of medicines over a 15 -year period (14). 
 
Encouragingly, most of the surveyed healthcare facilities had pharmacovigilance units that were 
functional. This is different to the situation that exists in a number of LMICs including public hospitals 
in South Africa (59). This is likely due to earlier concerted efforts by the Nigerian government, further 
corroborated by research findings on the information submitted to the National Pharmacovigilance 
Centre of Nigeria from many tertiary healthcare facilities (60, 61). Overall, periodic evaluation of 
medicine utilization including ADRs, with feedback to physicians, is useful for identifying medicine use 
patterns and associated problems such as the irrational use of medicines especially antimicrobials, 
potential drug-drug interactions and ADRs.  This type of periodic evaluation was rarely performed in 
the surveyed tertiary hospitals which is a concern.  Among DTCs in South Africa, both medicine 
utilization reviews (58%) and monitoring of ADRs (35%) are performed; however, again both are 
currently seen as sub-optimal (18). This urgently needs to be addressed in the future among Nigerian 
hospitals to improve future medicine use and patient safety. 
 
It is evident from this study that the suboptimal availability and functionality of DTCs within Nigerian 
healthcare institutions needs attention. A national policy for the establishment and functioning of 
DTCs with clear directives, and enforced as a regulatory or managerial intervention, would pave the 
way for the rational use of medicines and preserve scare resources. South Africa is an example of a 
LMIC where a functional DTC is now a regulatory requirement in terms of quality standards for all 
health establishments, in addition to a national policy for DTCs (59, 62-64). These are considerations 
for the future in Nigeria, and we believe this study highlights such a need. 
 
We are aware that this study has a number of limitations. This includes the fact that the number of 
tertiary healthcare facilities involved in this study is small and are all government owned. However, we 
believe the national spread of participating healthcare institutions is one of the strengths of this study 
as well as the initial selection of tertiary hospitals. The convenience sampling method is also a 
concern as it may not be statistically representative. However, the structure of tertiary healthcare 
facilities is similar throughout Nigeria and location so this is unlikely to affect the study outcome. 
However, future studies will address this issue. The issue of conflict of interest among members of 
DTCs and how they are handled was also not included in the questionnaire. This omission may affect 
to a certain extent the total picture of activities of DTCs emanating from this study. Future research on 
the activities of DTCs, especially of the qualitative type, is urgently needed to further investigate the 
understanding of stakeholders and dynamics of DTCs across both secondary and tertiary hospitals in 
Nigeria. This is also being planned for future projects alongside looking specifically at the influence of 
DTCs on improving the prescribing of specific medicine types such as antimicrobials. Never-the-less, 
we believe our findings are robust providing direction for the future not only in Nigeria but also wider.  
 
5. Conclusion 
 
DTC activities are currently limited in a substantial number of Nigerian tertiary healthcare facilities. In 
facilities with DTCs, many of the statutory functions and activities are currently not being carried out. 
This will continue to have a significant implication on the rational use of medicines in Nigeria, 
especially if these limited activities are seen, or worse, among secondary hospitals in Nigeria.  
 
Consequently, there is an urgent need for all key stakeholders in the healthcare sector to work 
towards the resuscitation and proper functioning of DTCs in healthcare facilities across the country. 
The supervising Ministry can initiate this process by mandating DTC activities in the first instance 
among government-owned tertiary level hospitals. They should be encouraged to instigate functioning 
DTCs within a specific time frame, especially among hospitals where such committees are currently 
non-existent or very limited. This builds on examples in other countries. There should also be 
measurable outcomes, including agreed treatment adherence rates to national guidelines in priority 
disease areas, robust systems in place for placing new medicines onto formularies, monitoring 
medicine utilization against agreed standards of care and feeding the findings back to physicians. In 
addition, generally educating physicians on the rational use of medicines. We will be using the 
findings from these studies to explore this with relevant Ministry of Health personnel, building in pro-
active examples from other African countries.  
 
6. Expert Commentary 
 
The irrational use of medicines increases healthcare costs and may negatively impact on patient 
outcomes. DTCs play an essential role in promoting rational and cost-effective use of medicines 
worldwide. This is very important in LMICs such as Nigeria where universal health care is lacking. The 
results of this study show the absence of DTCs in half of the surveyed tertiary facilities with poor 
functionality in centres where available. There were also major issues with antimicrobial sub-
committees, the ability to undertake pharmacoeconomic evaluations, and the availability of hospital 
formularies. In addition, the standard operating procedures were not well established in centres in 
tertiary hospitals with DTCs. These issues are a concern since if sub-optimal practices happen in 
tertiary facilities, the situation in secondary hospitals is likely to be worse. On the positive side, most 
centres had functioning drug information centres and pharmacovigilance units operating as separate 
entities. Overall findings of this study show that a lot more needs to be undertaken in the area of 
policy implementation and monitoring regarding DTCs in Nigeria to improve future care. Getting DTCs 
started and operational in healthcare facilities in the country will promote more cost-effective and 
rational use of medicines, logical uptake of new medicines and overall improve the quality of care and 
outcomes of patients. Future directions for research include assessing the knowledge and 
perspectives of healthcare workers on DTCs, as well as qualitative studies among DTC members to 
assess the processes of decision making and the level of implementation of their decisions. 
Introduction of new and expensive medications is a major function of the DTC; research into the 
patterns or procedures for introducing new medicines into healthcare facilities is something to be 
looked into in the near future in Nigeria building on activities among European countries. 
 
7. Five-year View 
We see DTCs evolving over the next five years in Nigeria with strides to improving access to 
medicines. However, the extent of such activities will depend on the influence and activities within the 
Nigerian Ministry of Health and translated down via directives and initiatives. The extent of DTC 
activities across all hospital sectors will also depend on the education of physicians and pharmacists 
whilst at Medical School or University. We do see greater physician education around the rational use 
of medicines to enhance the functioning of DTCs in Nigeria in the future. We have seen developments 
in the area of pharmacovigilance, and expect such developments with DTCs to assist with DTC 
activities in Nigeria in the future especially with concerns with current antimicrobial use in Nigeria and 
the subsequent impact on resistance rates and associated morbidity, mortality and costs in hospitals. 
The rates of non-communicable diseases are also a growing concern in LMICs including Nigeria 
impacting on morbidity and mortality, and again it is likely that DTC activities will involve to enhance 
the management of such patients in the future.  
 
We will continue to monitor the progress being made with DTC activities over the coming years 
through undertaking a number of planned studies on several critical aspects of DTCs. The results of 
these studies, when presented to stakeholders in the healthcare sector in Nigeria, will likely lead to 
expect greater involvement of the government especially in the area of making and enforcement of 
legislation in this regard. 
 
Key issues 
 
 This study shows the absence of DTCs in half of the surveyed healthcare facilities and poor 
functioning where present 
 Only 3 (50%) healthcare facilities had a sub-committee on antimicrobials while there was an 
overall lack of hospital formularies  
 Economic evaluation of medicines was only currently been undertaken in 3 (25%) of the surveyed 
healthcare facilities 
 Pharmacovigilance and Drug Information units were present in most of the participating centres 
(9; 75%) 
 The study identified a need for national policy on the establishment and functioning of DTCs in 
healthcare facilities to improve future use of medicines in hospitals in Nigeria 
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